PHIA Koninklijke Philips N.V.

One millionth procedure carried out on Philips Azurion advanced image-guided therapy platform

One millionth procedure carried out on Philips Azurion advanced image-guided therapy platform

November 27, 2019

Industry-leading platform combines clinical excellence and workflow innovation, helping clinicians and hospitals to deliver outstanding patient care

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the one millionth procedure on its flagship Azurion image-guided therapy platform. Since its introduction in February 2017, Azurion has seen rapid adoption in hospitals around the world, reaching the landmark millionth procedure in just over 2.5 years. The millionth procedure took place at GZA Ziekenhuizen in Antwerp, Belgium [1].

Image-guided therapy, where treatment is performed through a small incision and guided by imaging technologies including X-ray and ultrasound, is increasingly replacing open surgery for the treatment of many diseases. As the range of diseases that can be treated with image-guided therapy continues to expand and the procedures themselves become more efficient, the patient’s treatment experience continues to improve. They face less trauma, and as a result their stay in hospital can be dramatically reduced – often returning home after one night in hospital, and for some procedures even leaving the hospital on the same day.

“Minimally-invasive image-guided procedures are widely regarded as the answer to treating more patients, more quickly and at lower cost,” said Ronald Tabaksblat, General Manager Image Guided Therapy Systems at Philips. “Working together with clinicians, we use our comprehensive portfolio of interventional imaging systems, smart devices, software and services to treat one patient every second worldwide. The success of Philips Azurion is testament to the strength of the next-generation platform and our strategy of continuously innovating procedures to make them more effective and efficient.”

The procedure was carried out by Dr. Benoit Thomas, a thoracic and vascular surgeon at GZA Ziekenhuizen. Dr. Thomas’ patient was treated for a popliteal artery aneurysm – a bulge in the blood vessel behind the knee which, if left untreated, can potentially cause blood clots to form. Such a blood clot could cause the loss of the leg, a stroke or a heart attack. In the hospital’s hybrid operating room, the patient received a small endovascular stent graft – a tube-shaped structure inserted into the vessel to strengthen its walls.

“I’m proud to have treated the millionth patient with the Azurion, as this system has helped us to improve our workflow and improved the staff experience,” said Dr. Thomas. “A real benefit of the Azurion is that we can use previous diagnostic scans and reduce the amount of radiation for patients and staff. We also see an improvement in image quality and a decrease in procedure time due to the setup of the platform and the bedside control-panel.”

Most of today’s image-guided therapy procedures treat cardiovascular diseases, but its use is expanding into treatment of diseases in other organs such as the brain, lungs and spine.

Azurion: an industry-leading platform for image-guided therapy

Developed in collaboration with leading hospitals worldwide, Philips Azurion is an innovative image-guided therapy platform that allows clinicians to easily and confidently perform a wide range of routine and complex procedures, helping them to optimize interventional lab performance and provide superior care. Installed in more than 90 countries, the platform harnesses vital procedural information from various sources, such as imaging systems, interventional devices, navigation tools and patient health records to provide interventional staff with the control and information they need to perform procedures efficiently.

The latest addition to the image-guided therapy and Azurion portfolio is the , which includes a set of innovations that makes it easier for the clinician to perform imaging across the whole patient in both 2D and 3D and helps to reduce repositioning of the patient, staff and equipment. Philips also recently introduced the interventional applications platform to seamlessly integrate intravascular imaging and physiology applications into the interventional lab workflow.

Visit Philips at the RSNA 2019 annual meeting

During the Radiological Society of North America’s (RSNA) 2019 Annual Meeting, December 1-6, in Chicago, U.S., attendees will have the opportunity to experience Azurion first-hand at the Philips booth #6730. For more information about Philips’ presence at RSNA, visit and follow @PhilipsLiveFrom for #RSNA19 live updates.

[1] More than one million procedures have been performed on Philips Azurion based on Philips’ internal case and procedure data. The one millionth case was estimated based on the same data.

For further information, please contact:

Mark Groves

Philips Global Press Office

Tel:

Email:

Twitter:

Fabienne van der Feer

Philips Image Guided Therapy

Tel:

Email:

Twitter:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

 

Attachments

EN
27/11/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation ...

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI December 15, 2025 Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1] SpectraWAVE’s technologies have the potential to significantly increase adoption of corona...

 PRESS RELEASE

Philips reiterates timing of 2026 outlook

Philips reiterates timing of 2026 outlook December 4, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the company’s previously communicated schedule. As previously guided, the company expects continued performance improvement with sequential comparable sales growth, expanded margins (despite tariff headwinds) and strong cashflow. The company continues to expect comparative sales growth to accelerate sequentially in 2026 towards mid-single-digit gro...

 PRESS RELEASE

Philips expands commercial availability of world’s first real-time AI-...

Philips expands commercial availability of world’s first real-time AI-enabled light-based 3D navigation solution for image-guided therapy December 1, 2025 Commercial availability expanded across Europe and the United StatesReal-time AI-enabled 3D device visualization powered by light instead of X-ray, improving navigation in complex endovascular proceduresLumiGuide seamlessly integrates with Azurion, Philips’ proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains Amsterdam, the Netherlands and Chicago, USA – (NYSE: PHG, AEX: PH...

 PRESS RELEASE

Philips launches Verida, world’s first detector-based spectral CT powe...

Philips launches Verida, world’s first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision November 30, 2025 Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-reviewed publications [1]CE-marked, 510k pending Verida CT [2] integrates AI across the imaging chain, providing superb image quality while accelerating workflow and reducing dose [3, 4] Amsterdam, the Netherlands and Chicago, USA – At RSNA 2025, (NYSE: PHG, AEX: PHIA), a global leader in health techno...

 PRESS RELEASE

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MR...

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MRI platform November 30, 2025 Major technology breakthrough combines advanced AI for clinical insights and accelerated workflow in new premium 3.0T MRI platform [1] Amsterdam, the Netherlands, and Chicago, USA – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled BlueSeal Horizon [1], an entirely new 3.0T MRI innovation platform that includes the industry’s first helium-free 3.0T magnet at . A pivotal advance in MRI innovation, helium-free [2] 3.0T is a major scientific achievement set to have s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch